Latest News

Friday, October 20, 2017 | Cornea,Medical Studies

Newcastle Scientists Eye-Up Cornea 'Breakthrough'

Artificial corneas have been grown using a new method described as "revolutionary." Scientists at Newcastle University have developed a process they say makes them fit better and offer bette…

Read the full story

Friday, October 20, 2017 | Glaucoma,Partnerships, Nicox

Nicox Enters Research Collaboration with Re-Vana Therapeutics to Explore Drug Delivery Platform for the Reduction of IOP

Nicox SA and Re-Vana Therapeutics announced that they have entered into a research collaboration to explore combining Nicox’s next generation of stand-alone nitric oxide (NO)-donors with Re-Vana…

Read the full story

Friday, October 20, 2017 | Dry Eye

Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome

Aurinia Pharmaceuticals announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced…

Read the full story

Thursday, October 19, 2017 | Partnerships

Healthe and Corning Announce Collaboration on Technology to Help Protect Against Digital Device Blue Light Exposure

Healthe and Corning announced a collaboration to develop and introduce Eyesafe technology made with "Accessory Glass 2" by Corning. When integrated with Corning Glass, Eyesafe technology sel…

Read the full story

Thursday, October 19, 2017 | Clinical Trials,Retina, AMD, Genentech

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story

Thursday, October 19, 2017 | Fundraisers, Ziemer

Join Ziemer for Drinks at AAO and Support Hurricane Relief

Ziemer will make a donation for hurricane relief efforts for every hurricane cocktail served from the Ziemer Bar at the American Academy of Ophthalmology Meeting, November 11-14 at the Ernest N. Moria…

Read the full story

Thursday, October 19, 2017 | Dry Eye,Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals to Offer Compounded Cyclosporine

Imprimis Pharmaceuticals announced it is making compounded cyclosporine-based formulations for dry eye disease. The formulations, which will be packaged in a preservative-free bottle, are patent-pendi…

Read the full story

Thursday, October 19, 2017 | Medical Studies, American Academy of Ophthalmology

Genetic Testing Recommended for Children Considered at Risk for Most Common Eye Cancer

Children who are considered to be at risk of developing eye cancer should receive genetic counseling and testing as soon as possible to clarify risk for the disease. This is the consensus of leading o…

Read the full story

Thursday, October 19, 2017 | Acquisitions/Mergers,Blindness, AMD, Pixium Vision

Pixium Vision Receives Approval for First-in-Human Clinical Trial of PRIMA, Its Miniaturized Sub-Retinal Implant

Pixium Vision announced that its next-generation miniaturized wireless subretinal implant, PRIMA, aimed at restoring vision in patients affected by retinal dystrophies, received authorization from the…

Read the full story

Wednesday, October 18, 2017 | Earnings & Financials

Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases

Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, announced that it has completed a …

Read the full story

Wednesday, October 18, 2017 | Medical Studies

Ophthalmologists Spend Substantial Time on EHR Use

Ophthalmologists spent more than a quarter of their time with patients on electronic health records (EHRs), despite already having limited time overall to spend with patients, according to a single-ce…

Read the full story

Tuesday, October 17, 2017 | Clinical Trials

MeiraGTx Presents Preclinical Data on its Ocular Gene Therapy Studies for the Treatment of Leber's Congenital Amaurosis, Achromatopsia and X-Linked Retinitis Pigmentosa

MeiraGTx announced the presentation of preclinical data from studies in animal models of Leber's congenital amaurosis (LCA2), achromatopsia, and X-linked retinitis pigmentosa (XLRP) that support t…

Read the full story

Tuesday, October 17, 2017 | Glaucoma

iSTAR Medical Completes Enrollment of First-in-Human MIGS Trial

iSTAR Medical announced the completion of enrollment in their first-in-human microinvasive glaucoma surgery (MIGS) trial for the MINIject device. The first-in-human trial is a prospective, ope…

Read the full story

Tuesday, October 17, 2017 | Management/Leadership, Foundation Fighting Blindness

Benjamin Yerxa Named Foundation Fighting Blindness CEO

The Foundation Fighting Blindness (FFB) announced that it has selected Benjamin Yerxa, a biotechnology and drug development executive, as its Chief Executive Officer, effective immediately. The Fou…

Read the full story

Tuesday, October 17, 2017 | Medical Studies

NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis

NanoViricides will present the results of its anti-herpes nanoviricide treatment for Viral Acute Retinal Necrosis (vARN) at the 2017 Annual meeting of the Ocular Microbiology and Immunology Group (OMI…

Read the full story
Load More
 Stock Price  Change 
 ADVM $3.48  2.21% 
 Aerie Pharmaceuticals, Inc. $65.10  0.39% 
 Akorn, Inc. $33.28  0.39% 
 Alimera Sciences, Inc. $1.38  0.00% 
 Allergan $188.28  -0.52% 
 Applied Genetic Technologies $4.05  3.85% 
 Avalanche Biotechnologies $0.00  0.00% 
 Bayer $34.80  -1.16% 
 Can-Fite Biopharma $1.65  -0.60% 
 Carl Zeiss Meditec $44.87  -0.29% 
 Clearside Biomedical $7.90  0.13% 
 Cooper Companies, Inc. $235.35  -0.31% 
 Eleven Biotherapeutics $1.30  0.78% 
 Escalon Medical Corp. $0.14  7.69% 
 Essilor International $101.05  -0.44% 
 Glaukos $33.62  2.72% 
 Imprimis Pharmaceuticals, Inc. $1.85  -1.60% 
 Inotek Pharmaceuticals $2.38  2.15% 
 IRIDEX Corporation $9.52  -0.10% 
 Johnson & Johnson $142.40  0.25% 
 Luxottica Group, S.p.A. $60.90  0.41% 
 Merck & Company, Inc. $63.88  0.20% 
 NicOx $8.97  0.78% 
 NovaBay Pharmaceuticals, Inc. $4.30  -3.37% 
 Novartis AG Common Stock $85.74  -0.49% 
 Ocular Therapeutix $5.56  -1.24% 
 Ophthotech Corporation $2.41  -1.63% 
 QLT $1.95  0.00% 
 Quantel $7.06  -0.42% 
 Regeneron $432.98  -1.81% 
 Roche $29.73  -2.27% 
 Second Sight Medical Products $1.14  0.00% 
 Shire $145.25  -1.74% 
 Spark Therapeutics, Inc. $81.87  1.34% 
 STAAR Surgical Company $12.95  4.02% 
 TearLab Corporation $1.30  0.00% 
 Thrombogenics $5.01  -4.97% 
 Valeant Pharmaceuticals $12.13  -2.80% 
 Xoma $22.65  -2.66%